Stock Analiz

Nexgel, Inc. NXGL

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$3.88Market cap $2M
Open the interactive analysis →

Nexgel, Inc. (NXGL) is a healthcare company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $12M and net income of -$6M, a net margin of -51.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 76% a year, a 5-year average ROIC of -31%.

About Nexgel

Nexgel is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $2M in 2018 to $11M in 2025, growth of about 26.4% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 41% over three years (dilution for shareholders). It spends 0% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.2
P/B0.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-473.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)31.5%
Revenue growth (5 yrs, per year)76.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-130.2%
ROIC (5-yr avg.)-30.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$12M$11M$9M$4M$2M$2M$674000$717000$2M
Net income-$6M-$3M-$3M-$3M-$5M-$4M-$2M-$2M-$2M
Free cash flow-$10M-$1M-$4M-$4M-$3M-$3M-$2M-$2M—
EPS (diluted)$-10.65$-5.70$-7.50$-8.40$-12.75$-21.75$-15.75$-73.50$-199.50
Net margin-51.3%-26.3%-37.8%-77.2%-231.7%-277.9%-335.9%-268.2%-85.3%
ROIC—-36.6%-34.2%-37.0%-34.4%-12.4%-85.8%-117.2%-114.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Nexgel pay a dividend?

Not currently.

Is Nexgel a good stock to buy?

We do not give buy or sell advice. Nexgel scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.